These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 35586186)

  • 1. Pharmacokinetics and Safety of Single and Multiple Doses of Peficitinib (ASP015K) in Healthy Chinese Subjects.
    Gao X; He X; Oshima H; Miyatake D; Otsuka Y; Kato K; Cai C; Wojtkowski T; Song N; Kaneko Y; Shi A
    Drug Des Devel Ther; 2022; 16():1365-1381. PubMed ID: 35586186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function.
    Miyatake D; Shibata T; Toyoshima J; Kaneko Y; Oda K; Nishimura T; Katashima M; Sakaki M; Inoue K; Ito T; Uchida N; Furihata K; Urae A
    Clin Pharmacol Drug Dev; 2020 Aug; 9(6):699-708. PubMed ID: 31833184
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug Interactions Between Peficitinib, an Orally Administered, Once-Daily Janus Kinase Inhibitor, and Rosuvastatin in Healthy Subjects.
    Zhu T; Parker B; Wojtkowski T; Nishimura T; Garg JP; Han D; Fisniku O; Keirns J
    Clin Pharmacokinet; 2017 Jul; 56(7):747-757. PubMed ID: 27878567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics, Pharmacodynamics, and Safety of Peficitinib (ASP015K) in Healthy Male Caucasian and Japanese Subjects.
    Shibata M; Hatta T; Saito M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
    Clin Drug Investig; 2020 May; 40(5):469-484. PubMed ID: 32274653
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, Pharmacodynamics, and Safety of ASP015K (Peficitinib), a New Janus Kinase Inhibitor, in Healthy Subjects.
    Cao YJ; Sawamoto T; Valluri U; Cho K; Lewand M; Swan S; Lasseter K; Matson M; Holman J; Keirns J; Zhu T
    Clin Pharmacol Drug Dev; 2016 Nov; 5(6):435-449. PubMed ID: 27162173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Bioequivalence of Two Peficitinib Formulations, and the Effect of Food on the Pharmacokinetics of Peficitinib: Two-Way Crossover Studies of a Single Dose of 150 mg Peficitinib in Healthy Volunteers.
    Shibata M; Toyoshima J; Kaneko Y; Oda K; Kiyota T; Kambayashi A; Nishimura T
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):283-290. PubMed ID: 32618438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects with Normal and Impaired Renal Function.
    Miyatake D; Shibata T; Shibata M; Kaneko Y; Oda K; Nishimura T; Katashima M; Sekino H; Furihata K; Urae A
    Clin Drug Investig; 2020 Feb; 40(2):149-159. PubMed ID: 31729626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and effectiveness of peficitinib (ASP015K) in patients with rheumatoid arthritis: interim data (22.7 months mean peficitinib treatment) from a long-term, open-label extension study in Japan, Korea, and Taiwan.
    Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Song YW; Chen YH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Nakashima Y; Shiomi T; Yamada E
    Arthritis Res Ther; 2020 Mar; 22(1):47. PubMed ID: 32164762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Verapamil, a P-Glycoprotein Inhibitor, on the Pharmacokinetics of Peficitinib, an Orally Administered, Once-Daily JAK Inhibitor.
    Zhu T; Howieson C; Wojtkowski T; Garg JP; Han D; Fisniku O; Keirns J
    Clin Pharmacol Drug Dev; 2017 Nov; 6(6):548-555. PubMed ID: 28301084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Investigation of Potential Drug-Drug Interactions between Peficitinib (ASP015K) and Methotrexate in Patients with Rheumatoid Arthritis.
    Zhu T; Moy S; Valluri U; Cao Y; Zhang W; Sawamoto T; Chindalore V; Akinlade B
    Clin Drug Investig; 2020 Sep; 40(9):827-838. PubMed ID: 32591978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A drug-drug interaction study to evaluate the impact of peficitinib on OCT1- and MATE1-mediated transport of metformin in healthy volunteers.
    Shibata M; Toyoshima J; Kaneko Y; Oda K; Nishimura T
    Eur J Clin Pharmacol; 2020 Aug; 76(8):1135-1141. PubMed ID: 32472157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3).
    Tanaka Y; Takeuchi T; Tanaka S; Kawakami A; Iwasaki M; Song YW; Chen YH; Wei JC; Lee SH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Akazawa R; Shiomi T; Yamada E
    Ann Rheum Dis; 2019 Oct; 78(10):1320-1332. PubMed ID: 31350270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb study.
    Takeuchi T; Tanaka Y; Iwasaki M; Ishikura H; Saeki S; Kaneko Y
    Ann Rheum Dis; 2016 Jun; 75(6):1057-64. PubMed ID: 26672064
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 1, randomized study to evaluate safety, tolerability, and pharmacokinetics of GDC-3280, a potential novel anti-fibrotic small molecule, in healthy subjects.
    Cheung D; Fong A; Ding HT; Cabanski CR; Wang J; Chen Y; Bush J; Harris JM; Pan L
    Pulm Pharmacol Ther; 2021 Aug; 69():102051. PubMed ID: 34166834
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel JAK inhibitor, peficitinib, demonstrates potent efficacy in a rat adjuvant-induced arthritis model.
    Ito M; Yamazaki S; Yamagami K; Kuno M; Morita Y; Okuma K; Nakamura K; Chida N; Inami M; Inoue T; Shirakami S; Higashi Y
    J Pharmacol Sci; 2017 Jan; 133(1):25-33. PubMed ID: 28117214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study.
    Sands BE; Sandborn WJ; Feagan BG; Lichtenstein GR; Zhang H; Strauss R; Szapary P; Johanns J; Panes J; Vermeire S; O'Brien CD; Yang Z; Bertelsen K; Marano C;
    J Crohns Colitis; 2018 Nov; 12(10):1158-1169. PubMed ID: 29917064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan.
    Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Iwasaki M; Katayama K; Rokuda M; Izutsu H; Ushijima S; Kaneko Y; Shiomi T; Yamada E; van der Heijde D
    Ann Rheum Dis; 2019 Oct; 78(10):1305-1319. PubMed ID: 31350269
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Effectiveness of Peficitinib (ASP015K) in Patients with Rheumatoid Arthritis: Final Results (32 Months of Mean Peficitinib Treatment) From a Long-Term, Open-Label Extension Study in Japan, Korea, and Taiwan.
    Takeuchi T; Tanaka Y; Tanaka S; Kawakami A; Song YW; Chen YH; Rokuda M; Izutsu H; Ushijima S; Kaneko Y
    Rheumatol Ther; 2021 Mar; 8(1):425-442. PubMed ID: 33656739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor.
    Hamaguchi H; Amano Y; Moritomo A; Shirakami S; Nakajima Y; Nakai K; Nomura N; Ito M; Higashi Y; Inoue T
    Bioorg Med Chem; 2018 Oct; 26(18):4971-4983. PubMed ID: 30145050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.